Bankstown-Lidcombe Hospital is a principal referral group A1B hospital with tertiary affiliations to the University of New South Wales, University of Sydney and Western Sydney University providing a wide range of general medical and surgical services and sub-specialty services to the Bankstown/Canterbury community.

There are 454 beds in Bankstown-Lidcombe Hospital.

During the past decade, Bankstown-Lidcombe Hospital conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 12 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 11 clinical trials were completed. i.e. 110% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Bankstown-Lidcombe Hospital" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Arena Pharmaceuticals" with 2 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Sumitomo Pharma Oncology, Inc." with 2 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Bankstown-Lidcombe Hospital" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "Australasian Gastro-Intestinal Trials Group" with 2 trials as a collaborator, "Australian and New Zealand Intensive Care Society Clinical Trials Group" with 2 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator and "Cancer Research UK" with 2 trials as a collaborator. Other collaborators include 38 different institutions and companies that were collaborators in the rest 47 trials.

According to Clinical.Site data, the most researched conditions in "Bankstown-Lidcombe Hospital" are "Ulcerative Colitis" (6 trials), "Colorectal Cancer" (3 trials), "Breast Cancer" (2 trials), "Anxiety Disorder" (1 trials) and "Basilar Artery Occlusion" (1 trials). Many other conditions were trialed in "Bankstown-Lidcombe Hospital" in a lesser frequency.

Most popular intervention types in "Bankstown-Lidcombe Hospital" are "Drug" (32 trials), "Other" (9 trials), "Biological" (4 trials), "Procedure" (4 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Gemcitabine" (4 trials), "Bevacizumab" (3 trials), "Etrasimod" (3 trials) and "Etrolizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Bankstown-Lidcombe Hospital" are 32 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Bankstown-Lidcombe Hospital". undefined are not yet recruiting, 10 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Bankstown-Lidcombe Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Bankstown-Lidcombe Hospital, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".